Related Experiment Video
Updated: Jul 4, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Relationship between 25-Hydroxyvitamin D, bone density, and Parkinson's disease symptoms
Hui-Jun Zhang1, Jin-Ru Zhang1, Cheng-Jie Mao1
1Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Acta Neurologica Scandinavica
|August 8, 2019
Summary
Parkinson's disease patients often have low vitamin D, which correlates with increased falls and non-motor symptoms like insomnia and depression. Vitamin D supplementation may help manage these non-motor symptoms in Parkinson's disease.
Area of Science:
- Neurology
- Endocrinology
- Bone Health
Background:
- Vitamin D deficiency is prevalent in Parkinson's disease (PD) patients.
- Low vitamin D levels are associated with various non-motor symptoms and potentially bone health issues in PD.
Purpose of the Study:
- To investigate the correlation between serum vitamin D levels and bone mineral density (BMD) in Parkinson's disease patients.
- To examine the association between serum vitamin D levels and non-motor symptoms in individuals with PD.
Main Methods:
- Included 182 Parkinson's disease patients and 185 healthy controls.
- Measured serum 25-hydroxyvitamin D (25[OH]D) levels using immunoassay.
- Assessed bone mineral density (BMD) via dual-energy X-ray absorptiometry and analyzed associations using partial correlation.
Main Results:
- Parkinson's disease patients exhibited significantly lower serum 25(OH)D levels compared to controls.
- Lower vitamin D levels in PD patients correlated with higher frequencies of falls, insomnia, and elevated scores for sleep quality, depression, and anxiety.
- A significant association was found between vitamin D levels and falls, insomnia, sleep quality, depression, and anxiety in PD patients after adjusting for covariates.
Conclusions:
- Serum vitamin D levels significantly correlate with falls and several non-motor symptoms in Parkinson's disease.
- No significant association was observed between bone mineral density and serum 25(OH)D levels in this PD cohort.
- Vitamin D supplementation presents a potential therapeutic strategy for managing non-motor symptoms in Parkinson's disease.
Related Concept Videos
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Role of Vitamins in Maintaining Bone Health
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...